RxDoctor Payments Data

Mohammad Siddiqi, MD

Critical Care Medicine · Huntersville, NCNPI 1508150558

Payments from drug & device makers

$656in general payments, 2019–2025

Across 29 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$173
  • Teleflex LLC$127
  • Philips North America LLC$119
  • Takeda Pharmaceuticals U.S.A., Inc.$60
  • Covidien LP$58
  • Inogen, Inc.$42
  • plus $78 from 2 others

What the payments were for

  • Food & beverage$656100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$656 in reported general payments places this provider in the 65th percentile of 190 critical care medicine providers in North Carolina.

See all critical care medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$102,724
Medicare patients
328
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate21$316,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter180$167,363
Dupixent PenDupilumab17$63,615
Breo ElliptaFluticasone/Vilanterol123$59,555
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr82$54,027
Incruse ElliptaUmeclidinium Bromide90$37,938
Stiolto RespimatTiotropium Br/Olodaterol Hcl43$26,556
Spiriva RespimatTiotropium Bromide30$16,577
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$13,393
Arnuity ElliptaFluticasone Furoate55$13,382
Combivent RespimatIpratropium/Albuterol Sulfate18$12,829
Wixela InhubFluticasone Propion/Salmeterol32$8,753
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$7,190
Albuterol Sulfate HfaAlbuterol Sulfate210$5,804
Varenicline Tartrate15$3,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$173$332,264530 claims
AstraZenecaBreztri Aerosphere$41$13,39318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 190 critical care medicine providers in North Carolina.

Other critical care medicine in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →